Novo Nordisk plans to buy from the holding company three sites — Brussels; Anagni, Italy; and Bloomington — for $11.7 billion.

In a subsequent transaction, Novo Holdings plans to divest three of Catalent’s more-than-50 global sites to Novo Nordisk. These sites are located in Bloomington in the US state of Indiana, in Brussels ...

BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see ...

BRUSSELS (Reuters) -Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any ...

EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6 Stock Markets Published 11/04/2024, 03:01 AM Updated 11/04/2024, 11:16 AM ...

BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent, according to a filing on the European ...

BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent, according to a filing on the European ...

Catalent reiterated the deal is expected to close towards the end of 2024. After the deal closes, three of Catalent's fill-finish sites would be sold to Novo Nordisk for $11 billion.

FDA visited the company’s Brussels plant in October 2021 and August 2022. Reuters reported that “inspectors said the lapses at the plant … represented the most serious form of violations, according to ...

Novo Holdings expects to close the acquisition by the end of 2024, after which it will sell three of Catalent’s sites—in Anagni, Italy; Bloomington, Indiana; and Brussels, Belgium—to Novo ...

The parent company of Novo Nordisk agreed to pay $63.50 Per Share in Cash in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis. Notably, the FDA uncovered ...

Catalent's Brussels plant repeatedly breached US sterile-safety rules in 2021 and 2022 and staff failed to perform required quality checks, Reuters reported last year citing regulatory documents.